Table 2.
Subgroup analysis based on cancer type
| Outcome | Subgroup | Number of trials | Effect (95%CI) | Overall effect estimate | Heterogeneity |
|---|---|---|---|---|---|
| 1-Year OS | GC | 1 | 1.54 (0.99, 2.39) | P = 0.056 | – |
| CRC | 2 | 1.42 (1.21, 1.66) | P < 0.001 | I2 = 54.1%, P = 0.140 | |
| 3-Year OS | GC | 3 | 1.29 (1.12, 1.48) | P < 0.001 | I2 = 0%, P = 0.937 |
| CRC | 2 | 2.03 (1.41, 2.93) | P < 0.001 | I2 = 0%, P = 0.782 | |
| 5-Year OS | GC | 2 | 1.79 (1.31, 2.45) | P < 0.001 | I2 = 26.8%, P = 0.242 |
| CRC | 2 | 1.94 (1.18, 3.20) | P = 0.009 | I2 = 0%, P = 0.634 | |
| 1-Year PFS | GC | 1 | 1.41 (0.88, 2.26) | P = 0.155 | – |
| CRC | 2 | 1.33 (1.11, 1.60) | P = 0.002 | I2 = 0%, P = 0.940 | |
| 3-Year PFS | GC | 3 | 1.36 (1.14, 1.61) | P = 0.001 | I2 = 0%, P = 0.377 |
| CRC | 2 | 1.49 (1.10, 2.01) | P = 0.010 | I2 = 0%, P = 0.980 | |
| 5-Year PFS | GC | 2 | 2.25 (1.54, 3.29) | P < 0.001 | I2 = 0%, P = 0.493 |
| CRC | 2 | 1.73 (1.19, 2.52) | P = 0.004 | I2 = 0%, P = 0.854 | |
| PR | GC | 2 | 1.58 (0.70, 3.59) | P = 0.275 | I2 = 0%, P = 0.685 |
| CRC | 1 | 2.52 (0.71, 8.97) | P = 0.154 | – | |
| ORR | GC | 2 | 1.30 (0.81, 2.09) | P = 0.278 | I2 = 0%, P = 0.457 |
| CRC | 1 | 2.36 (0.79, 7.05) | P = 0.124 | – | |
| QOL | GC | 1 | 28 (26.36, 29.64) | P < 0.001 | – |
| CRC | 2 | 9.32 (6.96, 11.69) | P < 0.001 | I2 = 0%, P = 0.373 |
CRC Colorectal cancer, GC gastric cancer, ORR overall response rate, OS overall survival, PFS progression-free survival, PR partial response, QOL quality of life